Close
  Indian J Med Microbiol
 

Figure 1: Flowchart showing inclusion and exclusion criteria used to select the study population (n = 207) SDC = Steno Diabetes Center, T2DM = Type 2 diabetes mellitus, ATC = Anatomical Therapeutic Chemical, aGlucose-lowering medications investigated in this study included: Combinations of oral blood-glucose lowering medications (A10BD): Rosiglitazone-Metformin (Avandamet®), Sitagliptin-Metformin (Janumet®), Vildagliptin-Metformin (Eucreas®), Dipeptidyl peptidase-4 inhibitors (A10BH): Sitagliptin (Januvia®), Other blood glucose-lowering medications (A10BX): Repaglinide (NovoNorm®), Exenatide (Byetta®), Liraglutide (Victoza®)

Figure 1: Flowchart showing inclusion and exclusion criteria used to select the study population (<i>n</i> = 207) SDC = Steno Diabetes Center, T2DM = Type 2 diabetes mellitus, ATC = Anatomical Therapeutic Chemical, aGlucose-lowering medications investigated in this study included: Combinations of oral blood-glucose lowering medications (A10BD): Rosiglitazone-Metformin (Avandamet®), Sitagliptin-Metformin (Janumet®), Vildagliptin-Metformin (Eucreas®), Dipeptidyl peptidase-4 inhibitors (A10BH): Sitagliptin (Januvia®), Other blood glucose-lowering medications (A10BX): Repaglinide (NovoNorm®), Exenatide (Byetta®), Liraglutide (Victoza®)